Murat Terzi

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

Sean J. Pittock, Achim Berthele, Kazuo Fujihara et al. · New England Journal of Medicine · 2019 · 846 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

J William L Brown, Alasdair Coles, Dana Horáková et al. · JAMA · 2019 · 547 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Defining reliable disability outcomes in multiple sclerosis

Tomáš Kalinčík, Gary Cutter, Tim Spelman et al. · Brain · 2015 · 243 citations · Full text

Medicine, Neurology, Disability Management +16